Die Entzugsbehandlung von Gamma-Hydroxybuttersäure (GHB) im stationären Setting

Trotz eines relativ weit verbreiteten und zunehmenden Konsums von Gamma-Hydroxybuttersäure in der Partyszene gibt es nur wenige Berichte über die Behandlung der GHB-Abhängigkeit – meist mittels hoch dosierter Gabe von Benzodiazepinen nach einem individuellen Schema. Klare Behandlungsempfehlungen im Sinne einer Leitlinie liegen bisher nicht vor.

Schlüsselwörter

GBL - Gamma-Butyrolacton - BDO - 1,4-Butandiol - Substanzabhängigkeit - Drogenkonsum - Intoxikation

Keywords

GBL - gamma-butyrolactone - BDO - 1,4-butanol - substance dependence - drug use - intoxication

• Literatur

• 1 Molinaro S, Vincente J, Benedetti E. et al. ESPAD report 2019: results from European school survey project on alcohol and other drugs. European Monitoring Centre for Drugs and Drug Addiction; 2020;
• 2 Seitz N-N, Rauschert C, Kraus L. Europäische Schülerstudie zu Alkohol und anderen Drogen 2019 (ESPAD) Befragung von Schülerinnen und Schülern der 9. und 10. Klasse in Bayern. In: IFT-Berichte. München: Institut für Therapieforschung; 2020
• 3 Betzler F. GHB – Komplikationen im Entzug und ihre Vermeidung. In: SubLetter 4/2018. Würzburg: IWW Institut für Wissen in der Wirtschaft GmbH; 2018
• 4 Dijkstra BAG, Beurmanjer H, Goudriaan AE. et al. Unity in diversity: A systematic review on the GHB using population. Int J Drug Policy 2021; 94: 103230
• 5 Blumenfeld M, Suntay RG, Harmel MH. Sodium gamma-hydroxybutyric acid: a new anesthetic adjuvant. Anesth Analg 1962; 41: 721-726
• 6 Gertzen M, Strasburger M, Geiger J. et al. Chemsex: A new challenge in addiction medicine and infectious diseases. Nervenarzt 2022; 93: 263-278
• 7 Felmlee MA, Morse BL, Morris ME. γ-hydroxybutyric acid: pharmacokinetics, pharmacodynamics, and toxicology. AAPS J 2021; 23: 22
• 8 Nightingale SL. From the Food and Drug Administration. JAMA 1993; 270: 1672
• 9 Europäische Beobachtungsstelle für Drogen und Drogensucht. Europäischer Drogenbericht 2022: Trends und Entwicklungen. Luxembourg: Amt für Veröffentlichungen der Europäischen Union; 2022
• 10 Hammoud MA, Bourne A, Maher L. et al. Intensive sex partying with gamma-hydroxybutyrate: factors associated with using gamma-hydroxybutyrate for chemsex among Australian gay and bisexual men – results from the Flux Study. Sex Health 2018; 15: 123-134
• 11 Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337-361
• 12 Tunnicliff G. Sites of action of gamma-hydroxybutyrate (GHB) – a neuroactive drug with abuse potential. J Toxicol Clin Toxicol 1997; 35: 581-590
• 13 Madea B, Musshoff F. Knock-out drugs: their prevalence, modes of action, and means of detection. Dtsch Arztebl Int 2009; 106: 341-347
• 14 Kamal RM, van Noorden MS, Wannet W. et al. Pharmacological treatment in γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: detoxification and relapse prevention. CNS Drugs 2017; 31: 51-64
• 15 Leone MA, Vigna-Taglianti F, Avanzi G. et al. Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev 2010;
• 16 Skala K, Caputo F, Mirijello A. et al. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother 2014; 15: 245-257
• 17 Andresen H, Aydin BE, Mueller A. et al. An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 2011; 3: 560-568
• 18 Stein M. Stellungnahme zur nicht geringen Menge von Gamma-Hydroxybuttersäure. Toxichem und Krimtech 2003; 70: 87-92
• 19 Karlsson A, Sutherland R, Peacock A. Use of GHB amongst sentinel samples of people who regularly use illicit drugs in Adelaide, South Australia, 2020. Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney; 2021
• 20 Pistis M, Muntoni A, Pillolla G. et al. γ-Hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: Evidence for GABAB receptor-mediated effects. Neurosci 2005; 131: 465-474
• 21 The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms. J Toxicol Clin Toxicol [Anonym]. 2003; 41: 131-135
• 22 Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. Can J Emerg Med 2008; 10: 69-74
• 23 Perez E, Chu J, Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006; 48: 219-220
• 24 Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37: 147-153
• 25 Corkery JM, Loi B, Claridge H. et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev 2015; 53: 52-78
• 26 Bornovalova MA, Lejuez CW, Daughters SB. et al. Impulsivity as a common process across borderline personality and substance use disorders. Clin Psychol Rev 2005; 25: 790-812
• 27 Miotto K, Darakjian J, Basch J. et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10: 232-241
• 28 Bowles TM, Sommi RW, Amiri M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 2001; 21: 254-257
• 29 Mahr G, Bishop CL, Orringer DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001; 42: 439-440
• 30 Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat 2002; 23: 151-156
• 31 Domínguez I, Bruguera P, Balcells-Oliveró M. et al. Depression following γ-hydroxybutyrate withdrawal: A case report. J Clin Psychopharmacol 2015; 35: 618-619
• 32 Tay EM, Graham RI, Day RO. Severe GHB withdrawal delirium managed with dexmedetomidine. Med J Aust 2016; 205: 251-252
• 33 Bennett WR, Wilson LG, Roy-Byrne PP. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report. J Psychoactive Drugs 2007; 39: 293-296
• 34 Glasper A, McDonough M, Bearn J. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report. European addiction research 2005; 11: 152-154
• 35 Meyer R, Jenewein J, Boettger S. Management of gamma-butyrolactone dependence with assisted self-administration of GBL. Case Reports in Neurological Medicine 2014; 2014: 485178
• 36 Dijkstra BA, Kamal R, van Noorden MS. et al. Detoxification with titration and tapering in gamma-hydroxybutyrate (GHB) dependent patients: The Dutch GHB monitor project. Drug Alcohol Depend 2017; 170: 164-173
• 37 Beurmanjer H, Luykx JJ, De Wilde B. et al. Tapering with pharmaceutical GHB or benzodiazepines for detoxification in GHB-dependent patients: A matched-subject observational study of treatment-as-usual in Belgium and The Netherlands. CNS Drugs 2020; 34: 651-659
• 38 Olthof D, De Jong C, Dijkstra B. Praxisbezogene Empfehlungen zur Entzugsbehandlung bei GHB-Abhängigkeit. Nijmegen: Resultaten Scoren, NISPA; 2013